Autonomix Medical Inc

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies. The company was founded by Robert Schwartz, Landy Toth, David A. Robins, and Robert A. Van Tassel on June 10, 2014 and is headquartered in Doylestown, PA.

Preclinical study demonstrates potential of Autonomix technology to make renal denervation safer and more effective

Autonomix Announces Positive Findings from Preclinical Study Demonstrating Potential to Improve Renal Denervation

Live webcast with members of the Autonomix management team, on Thursday, April 11 th at 12:00 PM ET

Autonomix to Participate in the Virtual Investor Lunch Break: The Team Behind the AMIX Ticker

Live webcast presentation on Thursday, April 4 th at 3:55 PM ET THE WOODLANDS, TX, March 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Lori Bisson, Chief Executive Officer of Autonomix, will present at the MedInvest Biotech & Pharma Investor Conference being held in New York City, NY on Thursday, April 4, 2024 at 3:55 PM ET. In addition to the presentation, management will be available to participate in one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

Autonomix to Present at the MedInvest Biotech & Pharma Investor Conference

Live webcast presentation on Wednesday, March 20 th at 11:50 AM ET THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, announced today that Lori Bisson, Chief Executive Officer of Autonomix will present at the Benzinga Virtual Healthcare Summit 2024 on Wednesday, March 20, 2024 at 11:50 AM ET. Benzinga's Virtual Healthcare Summit is a virtual event where the brightest minds in healthcare, influential companies, analysts, and thought leaders converge to shape the future of health.

Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024

Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare, and medical technology brands

Autonomix Appoints Jennifer Cook as Chief Business Officer

First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer

Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Live webcast with Lori Bisson, Chief Executive Officer of Autonomix, on Thursday, February 29 th at 12:00 PM ET

Autonomix Medical, Inc. (NASDAQ: AMIX) to Participate in the Virtual Investor Lunch Break: The Autonomix Opportunity

Site initiation completed for first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer

Autonomix Begins Human POC Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market On track to commence first study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer in Q1 CY2024 Cash runway to fund operations into Q1 CY2025 THE WOODLANDS, TX, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, reported financial results yesterday for the third quarter FY2024 ended December 31, 2023 and provided a corporate update. Recent Highlights Closed $11.2 million in gross proceeds from initial public offering (“IPO”) and commenced trading on NASDAQ under the ticker symbol “AMIX”; Completed $8,000,000 all stock-based transaction for exclusive worldwide rights to technology for cardiology field use; Completed preclinical safety study to support program advancement into first in human clinical study to treat pancreatic cancer pain through transvascular ablation; Completed formation of engineering development team; Received Ethics Committee authorization for proof-of-concept (“PoC”) human clinical study evaluating proprietary ablation technology for treatment of pancreatic cancer pain; and Launched corporate social media channels: X , LinkedIn , Instagram and Facebook.

Autonomix Medical, Inc. Reports Third Quarter FY2024 Financial Results and Reiterates Upcoming Key Milestones

Webcast presentation on Wednesday, February 14th at 10:30 AM EST THE WOODLANDS, TX / ACCESSWIRE / February 9, 2024 / Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that Lori Bisson, Chief Executive Officer of Autonomix, will present at Integrous Communications' Big Hearts, Big Ideas Virtual Investor Conference on Wednesday, February 14, 2024 at 10:30 AM EST. In addition to the presentation, management will also be available to participate in virtual one-on-one meetings with qualified members of the investor community who are registered to attend the conference.

Autonomix Medical, Inc. (NASDAQ:AMIX) to Present at Integrous Big Hearts, Big Ideas Virtual Investor Conference

First study ever to evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer

Autonomix Medical, Inc. Receives Ethics Committee Authorization for Proof-of-Concept Human Clinical Study Evaluating Proprietary Ablation Technology for Treatment of Pancreatic Cancer Pain

Live moderated webcast with members of the Autonomix management team on Wednesday, February 7 th at 10:00 AM ET

Autonomix Medical, Inc. (NASDAQ: AMIX) to Present at the Virtual Investor New to the Street Event

THE WOODLANDS, TX., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that the Company will ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024 to celebrate the closing of its initial public offering and listing onto Nasdaq.

Autonomix Medical, Inc. to Ring the Nasdaq Stock Market Closing Bell on Thursday, February 1, 2024

Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix's development and strategic opportunities THE WOODLANDS, TX, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has regained exclusive worldwide rights to its technology for cardiology field use from Impulse Medical, Inc. In December 2021, Autonomix granted Impulse Medical, Inc., a license to its technology for use in the field of cardiology. In July 2023, the Company entered into a termination agreement for the license agreement in exchange for the issuance, upon the closing of its initial public offering, of a warrant to purchase the number of shares of common stock based upon a fixed value of $8 million divided by the price per share in the offering.

Autonomix Medical, Inc. Completes $8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use – Over 100 patents in portfolio

Autonomix now wholly owns development and commercialization rights to its technology in all indications Re-acquisition broadens Autonomix's development and strategic opportunities THE WOODLANDS, TX, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”) a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced that it has regained exclusive worldwide rights to its technology for cardiology field use from Impulse Medical, Inc. In December 2021, Autonomix granted Impulse Medical, Inc., a license to its technology for use in the field of cardiology. In July 2023, the Company entered into a termination agreement for the license agreement in exchange for the issuance, upon the closing of its initial public offering, of a non-cash warrant to purchase the number of shares of common stock based upon a fixed value of $8 million divided by the price per share in the offering.

Autonomix Medical, Inc. Completes Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use

Company developing potential breakthrough technology for the nervous system Initially targeting multi-billion-dollar pancreatic cancer market THE WOODLANDS, TX., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, announced its common stock will begin trading on the NASDAQ today, Monday, January 29, 2024 at approximately 10:30 am EST under the ticker symbol “AMIX.

Autonomix Medical, Inc. (NASDAQ: AMIX) Commences Trading on NASDAQ

Shares to begin trading on NASDAQ on January 29, 2024 under the ticker symbol “AMIX” THE WOODLANDS, TX., Jan. 26, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated, today announced the closing of its initial public offering of 2,234,222 shares of common stock priced at $5.00 per share.

News for Autonomix Medical Inc Stock (AMIX)